Affymax Inc. (NASDAQ:AFFY) up by 11.03%, DURECT Corporation (NASDAQ:DRRX)

Posted by Chris Bell May 13, 2013 0 Comment 1470 views


Miami, FL 05/13/2013 (GDPInsider) – Affymax, Inc. (NASDAQ:AFFY) is up by 11.03% in today’s trading session and currently trading at $1.52, after starting its day with a value of $1.32. The share up by about $0.16 from its previous close of $1.36 and ranged in between $1.30 and $1.65 till now. At a price of $1.52 and 12.18 million shares the total value of the company is more than $56.47 million. The earnings per share of the company is -$2.53. The 52-week trading range of the stock is $1.27 and $1.52. At the current levels the stock is trading below the 50 days MA of $1.22 but below its 200 days MA of $15.35. The RSI of the stock is 47.00.

The company announced that it will be unable to continue its operations due the losses incurred on the recall of its drug Omontys.

Is AFFY a solid investment at these levels? Get valuable updates and exclusive insights here.

DURECT Corporation (NASDAQ:DRRX) is down by 4.76% in today’s and currently trading at $1.00, after starting its day with a value of $1.10. The share down by about $0.05 from its previous close of $0.95 and ranged in between $0.96 and $1.10 during the day. At a price of $1.05 and 0.78 million shares the total value of the company is more than $101.88 million. The earnings per share of the company is -$0.19. The 52-week trading range of the stock is $0.61 and $1.85. At the current levels the stock is trading above the 50 days MA of $1.33 and above its 200 days MA of $1.16. The RSI of the stock is 33.81.

Pfizer Inc. (NYSE:PFE) the marketing partner of Pain announced that it is reassessing on continuing to seek regulatory approval for Remoxy a painkiller. The technology used in Remoxy is provided by DURECT.

How Should Investors Trade DRRX Now? Get the latest trends and data here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Chris Bell

Chris Bell is an investing reporter for GDP Insider. Chris covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Chris is also over consumer reporter and covers a wide variety of issues ranging from housing to immigration to urban poverty. Chris graduated from the University of Scranton with a degree in Communication and Philosophy. Chris's diligent investigations earned him the honor of being named "Best Reporter" once by the Headliners Foundation of Texas and once by the Houston Press Club.

View all post by Chris Bell Visit author's website

Write Your Comment